Clinical Study
Copeptin: Limited Usefulness in Early Stroke Differentiation?
Table 1
Patients’ characteristics.
| | Variables | All study patients () | Patients with stroke () | Patients with mimics () | Patients with TIA () |
| | Female % | 44 | 50 | 42.9 | 22 |
| | Age median (IQR) | 71 (54/76) | 68 (51/76) | 59 (53/83) | 71 (57/82) |
| | Medical history: | | | | |
| | Previous stroke in % () (unknown = 1) | 33 (12) | 40 (8) | 28 (2) | 22 (2) |
| | Previous TIA in % () | 6 (2) | 0 | 14 (1) | 11 (1) |
| | Copeptin in pmol/L Median (25%/75%) | 13.8 (9.1/48.5) | 19.1 (11.2/48.5) | 33.31 (7.57/255.7) | 9.4 (5.4/13.8) |
| | tPA administered in % () | 42 (15) | 70 (14) | 0 | 11 (1) |
| | Stroke severity, median NIHSS score (25%/75%) | 4 (2/9) | 7 (3/11) | 6 (1/9) | 2 (1/3) |
| | Length of inpatient stay in days Median (25%/75%) | 8 (4/10) | 9 (4/12) | 6 (5/8) | 6 (4/8) |
| TOAST score in % ()
Large artery atherosclerosis
Cardioembolism
Small vessel occlusion
Other determined aetiology
Undetermined aetiology
Unknown |
36.1 (13)
16.7 (6)
16.7 (6)
—
2.8 (1)
27.8 (10) |
55 (11)
15 (3)
15 (3)
—
—
15 (3) |
—
—
—
—
—
— |
22.2 (2)
33.3 (3)
22.2 (2)
—
—
22.2 (2) |
| Risk factors in % ()
Hypertension
Diabetes mellitus
Hypercholesterolemia
Neurologic disorders
Coronary heart disease |
83 (30)
33 (12)
19 (7)
22 (8)
11 (4) |
80 (16)
35 (7)
20 (4)
15 (3)
20 (4) |
86 (6)
29 (2)
14 (1)
43 (3)
0 |
67 (6)
33 (3)
22 (2)
22 (2)
0 |
| | Mortality within 1 year % () (unknown = 3) | 11 (4) | 19 (4) | 0 | 0 |
|
|
